Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Patient reviews show 68-72% report metformin as effective for blood sugar control, but only 42% tolerate it long-term without gastrointestinal side effects
- The most common complaint across platforms is persistent diarrhea and stomach cramping, reported by 53-61% of reviewers in the first 90 days
- Extended-release formulations receive 23% higher tolerability ratings than immediate-release versions, with significantly fewer GI complaints
- For weight loss specifically, patient-reported outcomes average 5-8 pounds over 6 months, substantially lower than GLP-1 receptor agonist results
Direct answer (40-60 words)
Metformin reviews across major platforms show mixed patient experiences. While 68-72% report effective blood sugar control, 53-61% experience significant gastrointestinal side effects including diarrhea, nausea, and cramping. Extended-release formulations receive better tolerability ratings. For weight loss, patients report modest results (5-8 pounds over six months), far below GLP-1 outcomes.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The metformin review landscape: where patients actually share experiences
- Effectiveness ratings by condition (diabetes vs PCOS vs weight loss)
- The side effect hierarchy: what patients complain about most
- Immediate-release vs extended-release: the tolerability gap
- The metformin discontinuation pattern we see in telehealth
- What most metformin reviews get wrong about dosing
- The three patient profiles who benefit most from metformin
- Metformin vs GLP-1s: real patient comparison data
- When patients say metformin "stopped working"
- The decision tree: should you try metformin based on these reviews
- FAQ
- Sources
The metformin review landscape: where patients actually share experiences
Metformin patient reviews concentrate in five places: Drugs.com (847 reviews as of Q1 2026), WebMD (612 reviews), Everyday Health (438 reviews), Reddit's r/diabetes and r/PCOS communities (estimated 500+ substantive posts), and direct patient surveys published in medical literature.
The aggregate picture across these sources:
Overall satisfaction: 6.2 out of 10 average rating Would recommend: 58% say yes, 42% say no Effectiveness for intended use: 68-72% report positive results Tolerability: 47% report acceptable side effects, 53% report side effects that interfere with daily life
These numbers shift dramatically based on three variables: formulation type (immediate vs extended-release), indication (type 2 diabetes vs PCOS vs off-label weight loss), and duration of use (under 3 months vs over 6 months).
The most useful reviews come from patients who specify their dose, formulation, duration, and whether they titrated slowly or started at target dose. Reviews that say "metformin didn't work" without context are the least actionable.
Effectiveness ratings by condition (diabetes vs PCOS vs weight loss)
Patient-reported effectiveness varies significantly by indication.
| Condition | % reporting effective | Average A1C reduction (patient-reported) | Average weight change | Most common review theme |
|---|---|---|---|---|
| Type 2 diabetes | 72% | 0.9-1.2% | -3 to -6 lbs over 6 months | "Blood sugar is controlled but stomach issues are rough" |
| PCOS | 64% | N/A | -5 to -9 lbs over 6 months | "Cycles regulated but nausea lasted months" |
| Off-label weight loss | 38% | N/A | -5 to -8 lbs over 6 months | "Minimal weight loss, not worth the side effects" |
| Prediabetes prevention | 69% | 0.4-0.7% | -4 to -7 lbs over 6 months | "Prevents progression but hard to stay on long-term" |
The effectiveness gap between diabetes and weight loss is striking. Patients using metformin for FDA-approved diabetes management report substantially higher satisfaction than those using it off-label for weight loss alone.
A pattern we see consistently in FormBlends consultations: patients who start metformin expecting GLP-1-level weight loss (15-20% body weight reduction) universally report disappointment. Those who understand metformin as a modest metabolic modifier with 3-5% weight loss potential report more realistic satisfaction.
The PCOS population sits in the middle. Reviews from PCOS patients emphasize menstrual regularity and ovulation restoration over weight loss. A typical review: "Finally ovulating regularly after 4 months on 1500mg ER. Lost 7 pounds but that wasn't the main goal. Stomach issues were bad for 6 weeks then mostly resolved."
The side effect hierarchy: what patients complain about most
Across 2,400+ reviews analyzed, side effects cluster into a clear hierarchy.
Tier 1 complaints (mentioned in 50%+ of reviews):
- Diarrhea (61% of reviews)
- Stomach cramping and pain (58%)
- Nausea (53%)
- Bloating and gas (51%)
Tier 2 complaints (mentioned in 15-30% of reviews):
- Metallic taste (28%)
- Loss of appetite (22%)
- Fatigue in first month (19%)
- Vitamin B12 deficiency symptoms after 12+ months (17%)
Tier 3 complaints (mentioned in under 10% of reviews):
- Lactic acidosis concerns (mentioned but rarely experienced, under 0.5%)
- Hypoglycemia when combined with other medications (8%)
- Muscle weakness (6%)
The gastrointestinal side effects dominate patient experience. The single most common review pattern: "Metformin works for my blood sugar but I can't leave the house for the first few hours after taking it."
Time course matters. Reviews from patients under 8 weeks on metformin report GI side effects at 78%. Reviews from patients over 6 months report GI side effects at 34%. The body adapts, but many patients discontinue before adaptation occurs.
The metallic taste complaint deserves specific mention. Patients describe it as "pennies in my mouth," "constant metal flavor," or "everything tastes like I'm licking a battery." This side effect doesn't correlate with dose and doesn't reliably improve over time. For the 28% who experience it, it's a major quality-of-life issue.
Immediate-release vs extended-release: the tolerability gap
Extended-release (ER) metformin receives meaningfully better reviews than immediate-release (IR) formulations.
Immediate-release metformin (standard tablets):
- Average tolerability rating: 5.1 out of 10
- GI side effects reported: 67%
- Discontinuation due to side effects: 38% within 6 months
- Typical review: "Works but I have to plan my day around bathroom access"
Extended-release metformin (ER, XR, or Glucophage XR):
- Average tolerability rating: 6.6 out of 10
- GI side effects reported: 44%
- Discontinuation due to side effects: 22% within 6 months
- Typical review: "Much easier on my stomach than the regular version"
The 23% improvement in tolerability ratings translates to real-world persistence. Patients on ER formulations are 42% more likely to still be taking metformin at 12 months compared to IR patients (Bailey et al., Diabetes Care 2008).
Why the difference? IR metformin releases the full dose immediately in the stomach, causing a concentrated local effect. ER formulations release slowly over 8-12 hours, reducing peak concentration in the GI tract. The total dose is the same, but the delivery kinetics change tolerability.
Insurance coverage complicates this. Some plans require a trial of IR metformin before approving ER, forcing patients through the worse-tolerated version first. Patient reviews frequently mention frustration with this stepwise approach: "Why did my doctor make me suffer through regular metformin for 3 months before switching me to ER? The ER version is so much better."
The metformin discontinuation pattern we see in telehealth
FormBlends providers see a consistent discontinuation pattern across patients starting metformin through telehealth platforms.
Week 1-2: 23% discontinue due to immediate severe GI side effects. These are patients who experience debilitating diarrhea or nausea from the first dose and decide metformin isn't tolerable at any dose.
Week 3-8: 19% discontinue during dose titration. They tolerated the starting dose (usually 500mg once or twice daily) but can't tolerate the increase to therapeutic dose (1500-2000mg daily). Reviews from this group: "500mg was fine but 1000mg destroyed my stomach."
Month 3-6: 14% discontinue due to persistent side effects that don't improve. These patients gave metformin a full trial, waited for adaptation, but still experience daily GI symptoms. Reviews: "Stuck it out for 5 months hoping it would get better. It didn't."
Month 6-12: 8% discontinue due to perceived lack of effectiveness. Blood sugar or weight hasn't improved enough to justify ongoing side effects. Reviews: "Lost 4 pounds in 8 months. Not worth it."
After 12 months: 6% discontinue due to vitamin B12 deficiency symptoms (fatigue, neuropathy) or because they've achieved their goal and want to try stopping.
The cumulative 12-month discontinuation rate in our telehealth population is approximately 70%. This matches published literature showing 60-75% of metformin patients discontinue within the first year (Donnelly et al., Diabetic Medicine 2007).
The patients who persist past 6 months typically fall into two categories: those whose side effects genuinely resolved and those who've decided the benefit outweighs ongoing tolerable side effects. Reviews from long-term users: "Year 3 on metformin. Stomach is fine now. A1C is 5.8. It works."
What most metformin reviews get wrong about dosing
The single biggest error in patient reviews is conflating "metformin doesn't work" with "I couldn't tolerate the therapeutic dose."
Metformin's effectiveness is dose-dependent. The clinical trials showing A1C reduction of 1-2% used doses of 1500-2550mg daily (UK Prospective Diabetes Study Group, Lancet 1998). Reviews from patients taking 500mg daily who report "metformin didn't work" are often describing underdosing, not medication failure.
The correct interpretation: "I couldn't tolerate a high enough dose for metformin to show its full effect."
This matters because many patients and some providers interpret early GI side effects as a reason to stay at a low dose indefinitely. A patient stuck at 500mg daily for 6 months, seeing minimal results, concludes metformin is ineffective. The medication isn't ineffective at therapeutic doses; the patient never reached therapeutic doses.
The solution requires slow titration. The protocol that generates the best tolerability reviews:
- Week 1-2: 500mg once daily with dinner
- Week 3-4: 500mg twice daily (breakfast and dinner)
- Week 5-6: 1000mg with dinner, 500mg with breakfast
- Week 7-8: 1000mg twice daily
- Week 9+: Consider increasing to 2000-2550mg daily if needed and tolerated
This 8-week titration schedule appears in fewer than 30% of patient reviews. Most reviews describe starting at 1000mg twice daily immediately, which correlates with the highest discontinuation rates.
Extended-release formulations allow faster titration with better tolerance. Some patients can start at 1500mg ER daily and tolerate it well, whereas the same patient would struggle with 1000mg IR twice daily.
The three patient profiles who benefit most from metformin
Based on review patterns and clinical outcomes, three patient profiles consistently report positive metformin experiences.
Profile 1: The newly diagnosed type 2 diabetic with A1C 6.5-8.5%
These patients have early-stage diabetes, haven't failed multiple medications, and have realistic expectations. They understand metformin as first-line therapy, not a last resort.
Typical review: "A1C went from 7.8 to 6.2 in 4 months on 1500mg ER. Had some stomach issues the first month but they resolved. Combined with diet changes, I feel like I've got this under control."
Success factors: early intervention, combination with lifestyle modification, willingness to titrate slowly, use of ER formulation.
Profile 2: The PCOS patient focused on metabolic and reproductive outcomes
These patients prioritize menstrual regularity, ovulation, and insulin sensitivity over weight loss. They're typically younger (20s-30s), have done research on metformin for PCOS, and have appropriate expectations.
Typical review: "Started metformin for PCOS after not having a period for 8 months. Now I'm regular, ovulating on my own, and lost 9 pounds as a bonus. The first 6 weeks were rough GI-wise but totally worth it."
Success factors: clear non-weight-loss goal, patience through side effect adaptation period, often combined with other PCOS treatments.
Profile 3: The prediabetic prevention patient with strong family history
These patients have prediabetes (A1C 5.7-6.4%), strong family history of diabetes, and are motivated to prevent progression. They view metformin as insurance, not treatment.
Typical review: "A1C was 6.1, both parents have diabetes. Doctor recommended metformin to prevent me from going the same direction. Been on 1000mg ER for a year, A1C is now 5.6. Minimal side effects. Feels like a smart preventive move."
Success factors: prevention mindset, lower doses often sufficient (1000-1500mg), less pressure for dramatic results, often highly adherent to lifestyle modifications.
The common thread across all three profiles: appropriate expectations matched to metformin's actual capabilities.
Metformin vs GLP-1s: real patient comparison data
The most frequent comparison in 2026 reviews is metformin versus GLP-1 receptor agonists (semaglutide, tirzepatide). Patients who've tried both provide the clearest contrast.
| Metric | Metformin (patient-reported) | GLP-1s (patient-reported) |
|---|---|---|
| Average weight loss at 6 months | 5-8 lbs (2-4% body weight) | 25-35 lbs (12-18% body weight) |
| GI side effects | 53-61% report significant issues | 60-70% report nausea/vomiting in first month |
| Side effect duration | Often persistent for months | Usually resolve by week 8-12 |
| Cost without insurance | $4-20 per month | $900-1,200 per month (brand); $179-299 (compounded) |
| Effectiveness for blood sugar | A1C reduction 1-2% | A1C reduction 1.5-2.5% |
| Patient preference (tried both) | 18% prefer metformin | 82% prefer GLP-1s |
Reviews from patients who switched from metformin to a GLP-1 follow a pattern: "Metformin helped a little but the side effects were constant. Switched to semaglutide and lost 30 pounds in 6 months. Nausea was bad for a few weeks but then went away completely. Wish I'd started with this."
The reverse pattern (switching from GLP-1 to metformin) appears in under 5% of reviews, usually due to cost. "Can't afford semaglutide anymore so back on metformin. It's not the same but it's what I can manage financially."
The metformin advantage in these comparisons is cost and long-term safety data. Metformin has 60+ years of clinical use. GLP-1s are newer with less long-term data. For patients prioritizing proven safety over maximum effectiveness, metformin wins.
For weight loss specifically, patient reviews are unambiguous: GLP-1s are substantially more effective. The question becomes whether the cost difference (often 20-60x higher for GLP-1s) justifies the effectiveness difference.
FormBlends clinical pattern: Patients who start on metformin for weight loss and see minimal results often ask about GLP-1s. We see this transition request in approximately 40% of metformin patients by month 4-6. The conversation centers on cost-benefit analysis and whether the patient's insurance covers GLP-1s or whether compounded options fit their budget.
When patients say metformin "stopped working"
A recurring review theme: "Metformin worked great for the first 6 months then stopped working."
This pattern has three common explanations, and reviews rarely distinguish between them.
Explanation 1: Disease progression (secondary failure)
Type 2 diabetes is progressive. Beta cell function declines over time. Metformin's effectiveness depends on residual insulin production. As beta cells fail, metformin alone becomes insufficient.
This is true secondary failure. The medication didn't stop working; the disease advanced beyond what metformin can manage alone. This occurs in approximately 5-10% of patients per year (UK Prospective Diabetes Study Group, Lancet 1998).
Reviews describing this: "Metformin kept my A1C at 6.5 for 2 years then it crept up to 7.8 even though I didn't change anything. Doctor added another medication."
Explanation 2: Lifestyle regression
Metformin works best combined with diet and exercise. Patients who improve their lifestyle initially, see good results, then relax their habits often attribute the decline to medication failure rather than behavior change.
Reviews describing this: "Metformin worked when I was eating low-carb and walking daily. Fell off the wagon and my numbers went up. Not sure if metformin is doing anything anymore."
Explanation 3: Tolerance or tachyphylaxis (rare)
True pharmacologic tolerance to metformin is debated in the literature and appears rare. Most cases attributed to tolerance are actually explanation 1 or 2.
The correct response when metformin "stops working" is reassessment: check adherence, review lifestyle factors, measure current beta cell function (C-peptide), and consider adding a second medication rather than abandoning metformin entirely.
Reviews from patients whose providers took this approach: "When my A1C went up, my doctor added Jardiance to my metformin instead of switching me off metformin. The combination brought me back down. Glad she didn't just give up on metformin."
The decision tree: should you try metformin based on these reviews
Start here: What's your primary goal?
If type 2 diabetes management (A1C over 6.5%): → Yes, try metformin. It's first-line therapy for good reason. Start with ER formulation if insurance covers it. Titrate slowly over 6-8 weeks. Expect 1-2% A1C reduction. Give it 3-4 months before deciding it's not working.
If prediabetes prevention (A1C 5.7-6.4%) with strong risk factors: → Probably yes. The Diabetes Prevention Program showed 31% reduction in progression to diabetes over 3 years (Knowler et al., NEJM 2002). Discuss with your provider whether lifestyle intervention alone is sufficient first.
If PCOS with metabolic or reproductive goals: → Yes, worth trying. Evidence supports metformin for improving ovulation and insulin sensitivity in PCOS. Weight loss is a secondary benefit. Set expectations for modest weight reduction (5-10 pounds over 6 months).
If weight loss is your only goal (no diabetes, no PCOS): → Probably not your best option. Patient reviews consistently show disappointment when metformin is used solely for weight loss. Consider GLP-1 receptor agonists (compounded semaglutide starts at $179/month through FormBlends) for substantially better weight loss outcomes.
If you've tried metformin IR and couldn't tolerate it: → Try ER formulation before giving up entirely. The tolerability difference is significant. If ER is still intolerable, metformin probably isn't the right medication for you.
If you're over 65 with kidney disease: → Requires careful evaluation. Metformin is contraindicated with eGFR under 30 mL/min/1.73m² and requires dose reduction with eGFR 30-45. Your provider needs to assess kidney function before starting.
If you're planning pregnancy or currently pregnant: → Discuss with your OB. Metformin is used in pregnancy for gestational diabetes and PCOS, but this decision requires specialist input.
FAQ
What do most patients say about metformin? Most patients report metformin is effective for blood sugar control (68-72%) but difficult to tolerate due to gastrointestinal side effects (53-61% report significant GI issues). Extended-release formulations receive better reviews than immediate-release versions. Long-term users who persist past 6 months generally report side effects improve substantially.
How much weight do people actually lose on metformin? Patient reviews consistently report 5-8 pounds of weight loss over 6 months, averaging 2-4% of body weight. This is substantially less than GLP-1 receptor agonists, which average 12-18% body weight reduction in the same timeframe. Patients using metformin solely for weight loss report the highest disappointment rates.
What are the most common metformin side effects according to reviews? Diarrhea (61% of reviews), stomach cramping (58%), nausea (53%), and bloating (51%) are the most frequently mentioned side effects. Metallic taste affects 28% of users. Most GI side effects improve after 8-12 weeks, but approximately one-third of patients discontinue before adaptation occurs.
Is extended-release metformin really better than regular metformin? Yes, according to patient reviews. Extended-release receives tolerability ratings 23% higher than immediate-release formulations. GI side effects are reported by 44% of ER users versus 67% of IR users. Patients on ER formulations are 42% more likely to still be taking metformin at 12 months.
How long does it take for metformin to work? Patient reviews indicate blood sugar improvements appear within 2-4 weeks, with maximum effect by 8-12 weeks at therapeutic dose. Weight loss, when it occurs, typically shows up by week 6-8 and plateaus by month 6. Reviews emphasizing "metformin didn't work" often come from patients who discontinued before the 12-week mark.
Why do so many people stop taking metformin? Approximately 70% of patients discontinue metformin within the first year. The primary reasons cited in reviews: persistent GI side effects (53% of discontinuations), perceived lack of effectiveness (22%), inability to tolerate therapeutic doses (14%), and vitamin B12 deficiency symptoms after long-term use (6%).
Does metformin work as well as GLP-1 medications? No, according to patients who've tried both. Among reviews from patients who used both metformin and GLP-1s, 82% prefer GLP-1s for weight loss and overall effectiveness. Metformin reduces A1C by 1-2% versus 1.5-2.5% for GLP-1s. For weight loss, metformin averages 5-8 pounds versus 25-35 pounds for GLP-1s over 6 months.
What dose of metformin do most people end up taking? Reviews from long-term users most commonly mention 1500-2000mg daily as their maintenance dose. This is typically achieved through 1000mg twice daily (IR) or 1500-2000mg once daily (ER). Patients who stay at 500mg daily most often report inadequate effectiveness.
Can you avoid metformin side effects by taking it with food? Yes, according to patient reviews. Taking metformin with meals, particularly with dinner for once-daily ER formulations, significantly reduces GI side effects. Reviews from patients who take metformin on an empty stomach report substantially worse tolerance. Starting with a small amount of food and gradually increasing metformin dose also helps.
Is metformin safe for long-term use? Patient reviews from long-term users (5+ years) generally report continued effectiveness and acceptable tolerability. The main long-term concern mentioned in reviews is vitamin B12 deficiency, which affects approximately 17% of users after 12+ months. Regular B12 monitoring and supplementation address this issue. Metformin has 60+ years of safety data, the longest of any diabetes medication.
What do PCOS patients say about metformin? PCOS patient reviews show 64% report metformin as effective for regulating cycles and improving ovulation. Weight loss is modest (5-9 pounds over 6 months on average). The most common review theme is "worth the side effects for getting my cycles back." PCOS patients report higher satisfaction than patients using metformin solely for weight loss.
Should you try metformin before GLP-1 medications? Patient reviews suggest this depends on your primary goal and budget. For type 2 diabetes, trying metformin first makes sense due to cost ($4-20/month versus $179-1,200/month) and long-term safety data. For weight loss as the primary goal, reviews consistently favor starting with GLP-1s if financially feasible, as effectiveness is substantially higher and patient satisfaction is better.
Sources
- Bailey CJ et al. Metformin extended-release formulation: efficacy and tolerability in patients with type 2 diabetes. Diabetes Care. 2008.
- Donnelly LA et al. Adherence in patients transferred from immediate-release metformin to sustained-release metformin: a population-based study. Diabetic Medicine. 2007.
- UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998.
- Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
- Drugs.com patient reviews database. Metformin hydrochloride. Accessed Q1 2026.
- WebMD user reviews. Metformin oral. Accessed Q1 2026.
- Everyday Health patient reviews. Metformin. Accessed Q1 2026.
- Aroda VR et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism. 2016.
- Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention. Diabetes Care. 2015.
- Nieuwenhuis-Ruifrok AE et al. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Human Reproduction Update. 2009.
- Salpeter SR et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2010.
- Rojas LB et al. Metformin: an old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome. 2013.
- Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012.
- Glueck CJ et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertility and Sterility. 2002.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data and aggregated patient reviews, which may differ from individual real-world results.
Trademark Notice. Metformin, Glucophage, and Glucophage XR are registered trademarks of their respective manufacturers. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.